36

CLAIMS

10

- 1. An isolated nucleic acid molecule comprising a nucleotide sequence selected from:
 - a) SEQ ID NO:3, or a fragment thereof;
 - b) SEQ ID NO:4, or a fragment thereof;
- 5 c) a sequence homologous to SEQ ID NO:3 or SEQ ID NO:4, or a fragment thereof;
 - d) a sequence that encodes a polypeptide comprising SEQ ID NO:5, or a fragment thereof; and
 - e) a sequence that encodes a polypeptide comprising an amino acid sequence homologous to SEQ ID NO:5, or a fragment thereof;

wherein the nucleic acid molecule encodes at least a portion of a tankyrase homolog protein.

- 2. The nucleic acid molecule of claim 1, which is DNA.
- 3. The nucleic acid molecule of claim 1, which is RNA.
- 15 4. The nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises SEQ ID NO:4.
 - 5. An isolated nucleic acid molecule comprising a nucleotide sequence complementary to at least a portion of SEQ ID NO:3 or SEQ ID NO:4, wherein a complement of the nucleic acid molecule encodes at least a portion of a tankyrase homolog protein.
- 20 6. The nucleic acid molecule of claim 5, which is an antisense oligonucleotide directed to SEQ ID NO:3 or SEQ ID NO:4.
 - 7. The nucleic acid molecule of claim 6, wherein the oligonucleotide is directed to a regulatory region of SEQ ID NO:3 or SEQ ID NO:4.
 - 8. The nucleic acid molecule of any preceding claim, for use in therapy or diagnosis.
- 25 9. An expression vector comprising a nucleic acid molecule of any preceding claim.
 - 10. The vector of claim 9, which is a plasmid or a viral particle.
 - 11. The vector of claim 10, which is selected from adenoviruses, parvoviruses, herpesviruses, poxviruses, adeno-associated viruses, Semliki Forest viruses, vaccinia viruses and retroviruses.
- 12. The vector of any of claims 9 to 11, wherein the nucleic acid molecule is operably connected to a promoter selected from simian virus 40, mouse mammary tumor virus, long terminal repeat of human immunodeficiency virus, Maloney virus, cytomegalovirus immediate early promoter, Epstein-Barr virus, Rous sarcoma virus, human actin, human myosin, human hemoglobin, human muscle creatine and human metalothionein.
- 35 13. The vector of any of claims 8 to 12, for use in therapy or diagnosis.

37

- 14. A host cell transformed with the vector of any of claims 9 to 12.
- 15. The host cell of claim 14, which is a bacterial cell, e.g. E. coli.
- 16. The host cell of claim 14, which is a yeast, e.g. S. cerevisiae.
- 17. The host cell of claim 14, which is an insect cell, e.g. is S. frugiperda.
- The host cell of claim 14, which is a mammalian cell, e.g. selected from chinese hamster ovary cells, HeLa cells, African green monkey kidney cells, human 293 cells and murine 3T3 fibroblasts.
 - 19. An isolated polypeptide encoded by the nucleic acid molecule of any of claims 1 to 8.
- 10 20. The polypeptide of claim 19, which comprises SEQ ID NO:5.
 - 21. The polypeptide of claim 19, which comprises an amino acid sequence homologous to SEQ ID NO:5.
 - 22. The polypeptide of claim 21, which comprises at least one conservative amino acid substitution compared to SEQ ID NO:5.
- 15 23. The polypeptide of claim 19, which comprises a fragment of SEQ ID NO:5.
 - 24. The polypeptide of any of claims 19 to 23, for use in therapy or diagnosis.
 - 25. Use of a polypeptide of any of claims 19 to 23, for the manufacture of a medicament for inducing an immune response to the polypeptide.
- 26. A method of producing a polypeptide comprising SEQ ID NO:5, or a homolog or fragment thereof, comprising the steps of:
 - a) introducing a vector of any of claims 9 to 12 into a compatible host cell;
 - b) growing the host cell under conditions for expression of the polypeptide; and
 - c) recovering the polypeptide.
- 25 27. The method of claim 25, wherein the host cell is lysed and the polypeptide is recovered from the lysate.
 - 28. The method of claim 26, wherein the polypeptide is recovered by purifying the culture medium without lysing the host cell.
- 29. An isolated antibody which binds to an epitope on a polypeptide of any of claims 30 19 to 23.
 - 30. The antibody of claim 29, which is a monoclonal antibody.
 - 31. The antibody of claim 29 or claim 30, for use in therapy or diagnosis.
 - 32. A kit comprising an antibody which binds to a polypeptide of any of claims 19 to 23, and a negative control antibody.

5

10

15

- 38
- 33. A method for identifying a compound which binds tankyrase homolog protein (THP), comprising contacting THP with a compound, and determining whether the compound binds THP.
- 34. The method of claim 33, wherein the determining comprises a protein binding assay, e.g. selected from a gel-shift assay, Western blot, radiolabeled competition assay, phage-based expression cloning, co-fractionation by chromatography, co-precipitation, cross-linking, interaction trap/two-hybrid analysis, southwestern analysis and ELISA.
- 35. A method for identifying a compound which binds a nucleic acid molecule encoding tankyrase homolog protein (THP), comprising contacting the nucleic acid molecule encoding THP with a compound, and determining whether the compound binds the nucleic acid molecule.
- 36. The method of claim 35, wherein the determining comprises a gel-shift assay.
- 37. A method for identifying a compound which modulates the activity of tankyrase homolog protein (THP), comprising contacting THP with a compound, and determining whether THP activity has been modulated.
- 38. The method of claim 37, wherein the activity is ADP-ribosylation or TRF1 binding.
- 39. A compound identified by the method of any of claims 34 to 38.